Lupin gets USFDA nod for Ethacrynic Acid Tablets
Pharma major Lupin on Monday informed the bourses that it has received approval from USFDA for its Ethacrynic Acid Tablets USP.
The company received USFDA approval for Ethacrynic Acid Tablets USP, 25 mg, from the United States Food and Drug Administration (USFDA). Lupin’s Ethacrynic Acid Tablets USP, 25 mg, is the generic version of Edecrin Tablets, 25 mg, of Bausch Health Americas, Inc.
The said medicine is used to decrease swelling (edema) caused by conditions such as cancer, congestive heart failure, liver disease, and kidney disease.
As per IQVIA data, the said drug had annual sales of US$24 million in the 12-month period ending June 2019 in the US market.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds a global leadership position in the Anti-TB segment.
On Monday, the shares of Lupin opened at Rs. 775 against its previous close of Rs. 772.50. It reached an intraday high of Rs. 778.55 and an intraday low of Rs 765.10 per share on the BSE. At 15:02, the stock was trading at Rs. 768.85 on the BSE. The 52-week high stood at Rs. 986.00 and the 52-week low was at Rs. 697.30 per share.